Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Blueprint Medicines Corp (BPMC): Biotechnology Value Fund Reports 10.4% Stake

Page 1 of 11

According to a recent 13G filing with the US Securities and Exchange Commission, Mark Lampert‘s Biotechnology Value Fund L. P. owns 2.84 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which amass 10.4% of the company’s outstanding stock. This is slightly more compared to 2.28 million shares Biotechnology Value Fund L. P. held in December, as reported in a previous filing.

Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Trade (NASDAQ:BPMC) Now!

Blueprint Medicines Corporation is a biopharmaceutical company that focuses on helping people suffering from genomically defined diseases driven by abnormal kinase activation. Over the past 12 months, the company’s shares have dropped by 18.51%. In March, a number of analysts updated their outlook on Blueprint Medicines Corporation’s stock, including JPMorgan Chase & Co., which lowered the price target to $37.00 from $54.00, while reporting “market outperform” rating. Blueprint Medicines Corporation is scheduled to report its financial results for the last quarter on May 10 and analysts project a loss of $0.70 per share on revenue of $3.24 million.

The number of long hedge fund positions, among those followed by Insider Monkey, in this stock has dropped by 1 recently. At the end of the third quarter of 2015, there were 14 hedge funds bullish on this stock, whereas at the end of the fourth quarter of 2015 there were 13 interested investors. At the end of December, Mark Lampert’s Biotechnology Value Fund L.P. reported the biggest position, worth around $60 million, and the second most bullish fund manager was Jacob Gottlieb of Visium Asset Management with a position worth about $26.9 million. Other hedge funds that have reported long positions in this stock are Christopher Medlock James’s Partner Fund Management, Peter Kolchinsky’s RA Capital Management, and Richard Driehaus’s Driehaus Capital.

Investors who lost interest in this stock and cut off their positions are Hal Mintz’s Sabby Capital, which dumped around $6.6 million in stock, and Israel Englander’s Millennium Management, which dropped a position worth around $0.7 million.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Trading Fund OS 0 170,320 0 170,320 170,320 Less than 1%
BVF Partners OS Ltd 0 170,320 0 170,320 170,320 Less than 1%
BVF Partners 0 2,840,251 0 2,840,251 2,840,251 10.4%
BVF Inc 0 2,840,251 0 2,840,251 2,840,251 10.4%
Mark N. Lampert 0 2,840,251 0 2,840,251 2,840,251 10.4%

Page 1 of 11 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 2)1
Blueprint Medicines Corporation
 (Name of Issuer)
Common Stock, $0.001 par value
 (Title of Class of Securities)
09627Y109
 (CUSIP Number)
April 29, 2016
 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   o  Rule 13d-1(b)
  x  Rule 13d-1(c)
   o  Rule 13d-1(d)

_______________
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
      The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Trade (NASDAQ:BPMC) Now!
Page 1 of 11
Loading Comments...